Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Design, recruitment, and baseline characteristics of the LENS trial

PREISS D. et al, (2024), Diabetic Medicine

Diabetic retinopathy and quality of life: A systematic review and Meta-analysis

Zayed M. et al, (2024), JAMA Ophthalmology

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial

Judge P. et al, (2023), Lancet Diabetes and Endocrinology

Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland

PREISS D. et al, (2023), BMJ Quality and Safety

Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.

Seekircher L. et al, (2023), Eur Heart J Open, 3

Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2022 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2022.

(2022), Circulation, 146, e569 - e605

Empagliflozin in Patients with Chronic Kidney Disease

HERRINGTON W. et al, (2022), New England Journal of Medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials

HERRINGTON W. et al, (2022), The Lancet

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017

PREISS D. et al, (2022), Heart

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Harmonization of large-scale, heterogeneous individual participant adverse event data from randomized trials of statin therapy

EMBERSON J. et al, (2022), Clinical Trials

Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease

Kohli-Lynch CN. et al, (2022), Circulation

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

HERRINGTON W., (2022), Nephrology, Dialysis and Transplantation

Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland

Thalmann I. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2328 - 2328

Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial

Preiss D. et al, (2022), CIRCULATION, 146, E577 - E577

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized trials

Preiss D. et al, (2022), DIABETES RESEARCH AND CLINICAL PRACTICE, 186

Impact of ACLY on type 2 diabetes in UK Biobank: a Mendelian randomisation study

Stiby A. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3011 - 3011

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials

PREISS D. et al, (2021), Diabetes Care

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?